Quantitative phenotypic and pathway profiling guides rational drug combination strategies

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Dawson, John C ^a   Carragher, Neil O ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Drug combinations; High content; Network pharmacology; Phenotypic screening; Proteomics

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMLODIPINE PLUS ATORVASTATIN; AMLODIPINE PLUS BENAZEPRIL; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBOPLATIN; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DABRAFENIB; DAPAGLIFLOZIN PLUS METFORMIN; DOCETAXEL; DOXORUBICIN; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EPIRUBICIN; EZETIMIBE PLUS SIMVASTATIN; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; IRINOTECAN; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; TRAMETINIB;

ANTIBIOTIC RESISTANCE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FUNCTIONAL PROTEOMICS; GRAM NEGATIVE INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PROTEIN MICROARRAY; SHORT SURVEY; VALIDATION PROCESS;

EID: 84904707337     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00118     Document Type: Short Survey

References (44)

1. Al-Lazikani, B., Banerji, U., and Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692. doi: 10.1038/nbt.2284
2. Alcock, P., Bath, C., Blackett, C., and Simpson, P. B. (2010). High content cell based primary screening for oncology targets - a perspective. Eur. Pharm. Rev. 3.
3. Axelrod, M., Gordon, V. L., Conaway, M., Tarcsafalvi, A., Neitzke, D. J., Gioeli, D., et al. (2013). Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget 4, 622-635.
4. Azmi, A. S., Wang, Z., Philip, P. A., Mohammad, R. M., and Sarkar, F. H. (2010). Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol. Cancer Ther. 9, 3137-3144. doi: 10.1158/1535-7163.MCT-10-0642
5. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., et al. (2012). The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607. doi: 10.1038/nature11003
6. Bickle, M. (2008). High-content screening: a new primary screening tool? IDrugs 11, 822-826.
7. Bickle, M. (2010). The beautiful cell: high-content screening in drug discovery. Anal. Bioanal. Chem. 398, 219-226. doi: 10.1007/s00216-010-3788-3
8. Caie, P. D., Walls, R. E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., et al. (2010). High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol. Cancer Ther. 9, 1913-1926. doi: 10.1158/1535-7163.MCT-09-1148
9. Cardnell, R. J., Feng, Y., Diao, L., Fan, Y. H., Masrorpour, F., Wang, J., et al. (2013). Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 19, 6322-6328. doi: 10.1158/1078-0432.CCR-13-1975
10. Carey, M. S., Agarwal, R., Gilks, B., Swenerton, K., Kalloger, S., Santos, J., et al. (2010). Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin. Cancer Res. 16, 2852-2860. doi: 10.1158/1078-0432.CCR-09-2502
11. Chou, T. C., and Talalay, P. (1981). Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115, 207-216. doi: 10.1111/j.1432-1033.1981.tb06218.x
12. Chou, T. C., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55. doi: 10.1016/0065-2571(84)90007-4
13. Cubitt, C. L., Menth, J., Dawson, J., Martinez, G. V., Foroutan, P., Morse, D. L., et al. (2013). Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma 2013:365723. doi: 10.1155/2013/365723
14. Dabhadkar, K. C., and Bellam, N. (2013). Polypill strategy for primary prevention of cardiovascular disorders. Drugs Today 49, 317-324. doi: 10.1358/dot.2013.49.5.1950148
15. Du, G. S., Pan, J. Z., Zhao, S. P., Zhu, Y., Den Toonder, J. M., and Fang, Q. (2013). Cell-based drug combination screening with a microfluidic droplet array system. Anal. Chem. 85, 6740-6747. doi: 10.1021/ac400688f
16. Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., et al. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321. doi: 10.1016/j.cell.2012.02.053
17. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703. doi: 10.1056/NEJMoa1210093
18. Harma, V., Virtanen, J., Makela, R., Happonen, A., Mpindi, J. P., Knuuttila, M., et al. (2010). A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 5:e10431. doi: 10.1371/journal.pone.0010431
19. Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., et al. (2013). Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov. 3, 52-67. doi: 10.1158/2159-8290.CD-12-0408
20. Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B., and Ram, P. T. (2010). Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 70, 6704-6714. doi: 10.1158/0008-5472.CAN-10-0460
21. Jabbour, S. A., Hardy, E., Sugg, J., and Parikh, S. (2014). Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37, 740-750. doi: 10.2337/dc13-0467
22. Kolch, W., and Pitt, A. (2010). Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10, 618-629. doi: 10.1038/nrc2900
23. Lee, J. A., and Berg, E. L. (2013). Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J. Biomol. Screen. 18, 1143-1155. doi: 10.1177/1087057113506118
24. Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., Macbeath, G., et al. (2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794. doi: 10.1016/j.cell.2012.03.031
25. Lehar, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., et al. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666. doi: 10.1038/nbt.1549
26. Li, X., Tong, L. J., Ding, J., and Meng, L. H. (2014). Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett. 342, 159-166. doi: 10.1016/j.canlet.2013.08.046
27. Mueller, C., Liotta, L. A., and Espina, V. (2010). Reverse phase protein microarrays advance to use in clinical trials. Mol. Oncol. 4, 461-481. doi: 10.1016/j.molonc.2010.09.003
28. Oikonomopoulos, G. M., Syrigos, K. N., Skoura, E., and Saif, M. W. (2014). FOLFIRINOX: from the ACCORD study to 2014. JOP 15, 103-105. doi: 10.6092/1590-8577/2278
29. Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F., and Altschuler, S. J. (2004). Multidimensional drug profiling by automated microscopy. Science 306, 1194-1198. doi: 10.1126/science.1100709
30. Sacks, L. V., and Behrman, R. E. (2009). Challenges, successes and hopes in the development of novel TB therapeutics. Future Med. Chem. 1, 749-756. doi: 10.4155/fmc.09.53
31. Sahoo, R. K., and Kumar, L. (2014). Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N. Engl. J. Med. 370, 478-479. doi: 10.1056/NEJMc1314761
32. Saltz, L. B., and Bach, P. B. (2014). Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N. Engl. J. Med. 370:478. doi: 10.1056/NEJMc1314761
33. Schmidt, L., Kling, T., Monsefi, N., Olsson, M., Hansson, C., Baskaran, S., et al. (2013). Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol. 15, 1469-1478. doi: 10.1093/neuonc/not111
34. Smith, G. S., Voyer-Grant, J. A., and Harauz, G. (2012). Monitoring cleaved caspase-3 activity and apoptosis of immortalized oligodendroglial cells using live-cell imaging and cleaveable fluorogenic-dye substrates following potassium-induced membrane depolarization. J. Vis. Exp. e3422. doi: 10.3791/3422
35. Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290. doi: 10.1126/science.1142946
36. Tanaka, M., Bateman, R., Rauh, D., Vaisberg, E., Ramachandani, S., Zhang, C., et al. (2005). An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3:e128. doi: 10.1371/journal.pbio.0030128
37. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., et al. (2006). Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512-2521. doi: 10.1158/1535-7163.MCT-06-0334
38. Von Hoff, D. D., Goldstein, D., and Renschler, M. F. (2014). Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N. Engl. J. Med. 370, 479-480. doi: 10.1056/NEJMc1314761
39. Voshol, H., Ehrat, M., Traenkle, J., Bertrand, E., and Van Oostrum, J. (2009). Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J. 276, 6871-6879. doi: 10.1111/j.1742-4658.2009.07395.x
40. Weissenstein, U., Schneider, M. J., Pawlak, M., Cicenas, J., Eppenberger-Castori, S., Oroszlan, P., et al. (2006). Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 6, 1427-1436. doi: 10.1002/pmic.200500078
41. Yap, T. A., Omlin, A., and De Bono, J. S. (2013). Development of therapeutic combinations targeting major cancer signaling pathways. J. Clin. Oncol. 31, 1592-1605. doi: 10.1200/JCO.2011.37.6418
42. Yarrow, J. C., Perlman, Z. E., Westwood, N. J., and Mitchison, T. J. (2004). A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol. 4:21. doi: 10.1186/1472-6750-4-21
43. Zimmermann, G. R., Lehar, J., and Keith, C. T. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42. doi: 10.1016/j.drudis.2006.11.008
44. Zinner, R. G., Barrett, B. L., Popova, E., Damien, P., Volgin, A. Y., Gelovani, J. G., et al. (2009). Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol. Cancer Ther. 8, 521-532. doi: 10.1158/1535-7163.MCT-08-0937